Beta Thalassemia Treatment

View All

what-is-the-future-of-beta-thalassemia-market
Beta Thalassemia Treatment – Insights Into the Challenges & Solutions

Beta Thalassemia (β-Thalassemia) is a blood disorder characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin ana...

Find More

Beta thalassemia market
How Gene therapy is changing the Beta-thalassemia Treatment outlook?

Beta thalassemia, globally affects almost 288,000 people, with an incidence of 60,000 cases every year. A rare monogenic genetic disease, beta-thalassemia is caused by more than 200 mutations of the beta-globin gene (HBB). The Beta-thalassemia pharmacological treatment mainly comprises of regular blood-transfus...

Find More